SCHEMBL22939418

SCHEMBL22939418

Cc1ccc(-c2cc(C(=O)Nc3ccc(OC(F)(F)Cl)cc3)cc3c2C(C)(C)N(C)C3=O)s1

nearest known ligand 0.48

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 20/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30046805 1.00 ABL1 (0.48) ABL1
SCHEMBL28523803 0.85 ABL1 (0.54) ABL1
SCHEMBL30046925 0.85 ABL1 (0.53) ABL1
SCHEMBL22939415 0.85 ABL1 (0.53) ABL1
SCHEMBL22938646 0.83 ABL1 (0.56) ABL1
SCHEMBL30046582 0.83 ABL1 (0.56) ABL1
SCHEMBL28518646 0.83 ABL1 (0.46) ABL1
SCHEMBL22938707 0.82 ABL1 (0.64) ABL1
SCHEMBL30046879 0.82 ABL1 (0.64) ABL1
SCHEMBL28526329 0.75 ABL1 (0.49) ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112300129-B Heterocyclic compounds as BCR-ABL inhibitors 苏州亚盛药业有限公司 2021-09-14 — — CN claimed
CN-112300129-B Heterocyclic compounds as BCR-ABL inhibitors 苏州亚盛药业有限公司 2021-09-14 — — CN disclosed
WO-2021018194-A1 HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-02-04 — — WO disclosed
CN-112300129-A Heterocyclic compounds as BCR-ABL inhibitors 苏州亚盛药业有限公司 2021-02-02 — — CN disclosed
Send feedback